As a preformed defense system, complement faces a delicate challenge in providing an immediate, forceful response to pathogens even at first encounter, while sparing host cells in the process. For this purpose, it engages a tightly regulated network of plasma This article is part of a series of reviews covering Preformed Mediators of
At the dawn of the 20th century and of modern immunology, studies of the bactericidal activity of blood serum led to the discovery of the complement system, and it soon became evident that this cascade acts as a critical first-line responder of innate immunity.
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Initially thought to be composed of nine distinct components (i.e. C1-C9), the number of associated molecules grew with our increasing knowledge about the functional and molecular characteristics of complement. Today, we consider some 50 proteins, encompassing both plasma proteins and membrane-bound receptors/regulators, to belong of the complement system, forming a tightly knit and highly cooperative surveillance network. 3, 4 Since its initial description as an antibody-"complementing" bactericidal blood component, the perception of complement has dramatically changed and now involves much broader functions in immune surveillance, homeostasis and development, tissue-localized and intracellular activities, and intense crosstalk with many physiological pathways. [3] [4] [5] The sensing and elimination of microbial intruders and other potential insults still remains a core function of complement and is largely maintained by the core cascade system ( Figure 1A ).
| C3-mediated opsonization as central element in the elimination of threats
Once they encounter a pathogen or other foreign cell, the various PRMs of the complement system detect and bind to distinct surface patterns and induce the cascade via several routes. 3, 4, 6 Although the classical pathway (CP) is induced by the C1 complex, which primarily binds to antibody complexes and also to other pathogen-or damageassociated molecular patterns (PAMPs, DAMPs), the various PRMs of the lectin pathway (LP) recognize microbial carbohydrates and similar markers ( Figure 1A ). In all cases, PRM-associated proteases become activated and cleave components C2 and C4 to form a reactive but unstable protease complex on the surface of the targeted cells; this CP/LP C3 convertase binds to and cleaves the abundant plasma protein C3 and induces a transformation that determines the fate of the cell. The convertase-mediated cleavage of C3 releases the small protein C3a and induces a conformational change in the remaining C3b fragment that exposes a highly reactive but short-lived thioester. In close proximity to the initiating surface, the newly formed C3b can covalently bind to hydroxyl or amino groups, thereby opsonizing the cell. Importantly, formation of C3b enables the binding of the protease Factor B (FB), and the resulting pro-convertase (i.e. C3bB) is quickly transformed by Factor D (FD) into an active C3 convertase (i.e.
C3bBb) that by itself can cleave more C3 into C3b, thereby creating an amplification loop for C3b deposition ( Figure 1C ). This mechanism is
commonly, yet somewhat misleadingly referred to as the "alternative pathway" (AP) of complement, especially as this route can sometimes contribute up to 80% of the overall response, even after initiation by the CP or LP. 7, 8 Although not pathogen-specific, CP-and LP-mediated initiation still confers some selectivity, as these routes are dependent on the presence of certain microbial surface markers or, as in the case of antibody-mediated CP activation, receive assistance from adaptive immunity. However, complement also employs a simple yet elegant "tick-over" mechanism involving C3 that allows the system to increase baseline activity and probe cells in a less distinctive manner ( Figure 1B ): Although C3 predominantly circulates in its native form, a small fraction is constantly undergoing spontaneous hydrolysis to result in a distinct conformer termed C3(H 2 O). Without changing its composition, C3 thereby modifies its reactivity as a result of structural changes that generate a molecule with a functional spectrum similar to that of C3b. As such, C3(H 2 O) can bind FB and form AP C3 convertases that turn C3 into C3b and initiate the AP. Importantly, physical adsorption of C3 on various surfaces, such as microbial cells containing lipopolysaccharides (LPS) and also blood-gas interfaces or activated platelets, can induce a similar conformational activation in C3 ( Figure 1B ), thereby enhancing and directing the tick-over in the case of less-defined threats. 9 Finally, C3 may be directly cleaved by non-convertase proteases such as coagulation enzymes (e.g. thrombin, plasmin) or tissue kallikreins 10, 11 ;
although these activities are typically low in comparison with the primary substrates, it is possible that this "extrinsic" pathway ( Figure 1A ) gains relevance under specific disease conditions or in local microenvironments.
Independent of the route of initiation, opsonization with C3b
marks the starting point for the generation of a series of potent effectors with the aim of facilitating the clearance of the tagged particles ( Figure 1D ). In this context, C3b not only amplifies the complement response via convertase formation but also acts as an effector itself that mediated functions in innate and adaptive immunity. is a highly versatile effector that not only maintains binding activity for CRIg but also gains affinity for the phagocytic integrin receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18), thereby largely enhancing complement-mediated phagocytosis. Intriguingly, there is increasing evidence that the powerful iC3b-CR3 mechanisms are not only employed for microbial clearance but also for immunoediting during tissue development; recent studies have shown that complement is engaged during synaptic pruning with potential implications for the development of schizophrenia. 13, 14 Finally, the conversion to iC3b also exposes a binding site for CR2 (CD21); this receptor is ex- Interestingly, recent studies suggest that the interaction profile of C3dg with the related receptors CR3 and CR4 is distinct. C3dg still contains binding sites for CR3 and, at least in the case of densely C3dg-opsonized erythrocytes, the C3dg-CR3 interaction can mediate phagocytosis; the relevance of this mechanism in the context of different (patho)physiological scenarios needs to be further explored. In any case, the deposition and conversion of C3b provides a dynamic platform for tiered effector functions ranging from immune adherence and transport (C3b-CR1) to phagocytosis (C3b/iC3b-CRIg, iC3b/C3dg-CR3, iC3b-CR4) and adaptive immune modulation (C3b-CD46, iC3b/C3d-CD21).
Although some aspects remain elusive, C3b is also essential for the induction of the terminal pathway of complement effector generation ( Figure 1A , E). Increasing the density of C3b during complement activation and amplification leads to a substrate specificity shift in the generated convertases from C3 to its paralog C5. Although the CP/LP C3 convertases are composed of cleavage-generated C4 and
F I G U R E 1
The various roles of C3 in complement activation and effector functions. (A) Schematic representation of the complement cascade. Initiation of classical and lectin pathway (CP, LP) via pattern recognition molecules, and of the alternative pathway via tick-over or adsorption, leads to the formation of initial C3 convertases, which activate C3. C3 can also be cleaved directly by extrinsic proteases. Independent of the activation route, the cleavage product C3b can form new convertases after engagement of factor B and D (FB, FD), thereby fueling an amplification loop that leads to rapid opsonization of the target surface with C3b. Increasing C3b densities facilitate the formation of C5 convertases that initiate the terminal pathway with generation of the lytic membrane attack complex (MAC) and the potent anaphylatoxin C5a. At the same time, C3 fragments exert direct effector functions. Although C3a binds to the anaphylatoxin receptor C3aR, C3b and its degradation products iC3b and C3dg interact with a variety of complement receptors (CR) to mediate immune adhesion, phagocytosis, and adaptive immune stimulation. Properdin (factor P, FP) enhances convertase stability, but regulators of complement activation (RCA) promote its decay and enable the degradation of C3b. (B) C3-induced complement initiation via hydrolysis in solution and physical adsorption on surfaces (i.e. "tick-over") or via proposed capturing by bridging molecules such as properdin or P-selectin. (C) Amplification of the initial complement response, driven by the formation of C3bBb complexes via interaction of C3b with FB to form the pro-convertase C3bB and subsequent activation by FD. (D) Examples of major effector functions of C3 fragments, including chemotaxis and cell activation via C3a, phagocytosis of opsonized particles, immune adhesion and shuttling, and adaptive modulation via B-and T-cell stimulation. (E) Induction of the terminal pathway by increasing densities of C3b, leading to the generation of C5a and MAC. Ab, antibody; Ag, antigen; BCR, B-cell receptor; C3aR, C3a receptor; C5aR1, C5a receptor 1 (CD88); C5aR2, C5a receptor 2 (C5L2); CL-11, collectin 11; CRIg, CR of the immunoglobulin family; Fcn, ficolins; FI, factor I; MASP, MBL-associated serine protease; MBL, mannose-binding lectin; PAMP, pathogen-associated molecular patterns; RBC, red blood cell; TCR, T-cell receptor C2 fragments, an association with C3b is necessary for shifting to C5 convertase activity. Once formed, C5 convertases cleave C5 into C5b, thereby releasing the small C5a protein. In contrast to C3b and C4b, C5b does not covalently deposit via a thioester, but rather associates with C6 and C7 to form a complex that can insert into membranes.
The binding of C8 and multiple copies of C9 forms the membrane attack complex (MAC) that acts as a lytic pore to damage or kill susceptible cells and organisms.
| Spreading the danger signal: The role of C3a
Although MAC-induced lysis and opsonin-mediated phagocytosis already represent efficient means of microbial clearance, the translation of local complement activation into cellular signals and the coordination of downstream responses add another critical layer to complement's defensive actions. Alongside the immunomodulatory activities of opsonins, which act in direct contact with target and effector cells (see above), the remote actions of the anaphylatoxins C3a and C5a are highly important for shaping the immune response ( Figure 1A ). C5a, in particular, is a powerful chemoattractant that signals via two C5a receptors (C5aR1/CD88, C5aR2/C5L2) and exerts activities that range from immune cell activation and priming to smooth muscle contraction and beyond. In addition, C5a-mediated signaling is engaged in a plethora of crosstalk activities with other defense and homeostatic pathways.
C3a has long been considered a less potent cousin of C5a, with a similar activity spectrum but a 10-to 100-fold weaker activity.
However, newer studies have suggested that C3a, which signals through the G protein-coupled C3a receptor (C3aR), shows a distinct and context-specific profile that sometimes even counteracts C5a-induced activities. 15 In fact, C3a appears to assist in some unique functions, with our group and others having demonstrated its involvement in such diverse processes as tissue development and regeneration (e.g.
in the retina, liver), [16] [17] [18] [19] also been reported to act as a preformed mediator of defense outside its role in complement, as it may act as an antimicrobial peptide that binds to and destabilizes bacterial membranes. 26 Although many aspects of its function remain to be fully explored, C3a appears to hold a few more functional cards than initially thought.
| Tuning C3 activity through interaction with modulators and regulators
The molecular pattern on a cell surface largely defines the binding of PRMs and/or adhesion of C3; complement is therefore intrinsically less likely to be engaged on host cells than on foreign particles.
However, given the potentially deleterious actions of an activated complement system on or near host cells, circulating and membranebound complement regulators offer an essential layer of protection and confer the necessary selectivity. Although soluble C1 inhibitor and non-proteolytic splice products of MASPs help control the CP and/or LP, membrane-bound CD59 prevents the formation of MAC, and carboxypeptidases tame/modulate anaphylatoxin activity. 27 Given their central role in modulating complement activity, however, Figure 1B) ; however, the relevance of this bridging function is still debated. [33] [34] [35] Although the molecular details remain to be elucidated, there is increasing evidence for a recruitment of C3b by P-selectin on platelets and endothelial cells that could induce or exacerbate complement activation. 36 FH-related proteins (FHRs) contain domains homologous to the C-terminal region of FH, which binds both C3b/iC3b/ C3dg and self-surface patterns. As a consequence, they can compete with FH for host surface binding and de-regulate complement activity on certain surfaces such as apoptotic cells. 37, 38 Finally, members of the pentraxin family are known as context-specific modulators of complement activity but seem to mediate their activity via binding to PRMs and regulators rather than by directly interacting with C3 
| C3 AS AN EVOLUTIONARILY CONSERVED CORNERSTONE OF IMMUNOLOGY
Delving into the evolutionary history of C3, and of the complement system in general, has provided valuable insight into its multifaceted roles in host immunosurveillance, tissue homeostasis, and adaptive immune regulation. 40, 41 Indeed, C3 homologs and C3-mediated activities have been characterized in evolutionarily distant species ranging from the most primitive invertebrates, the Cnidaria, and certain protostomes (e.g. arthropods) to diverse members of the deuterostome lineage of the metazoans, including echinoderms, urochordates, lower vertebrates, and mammals ( Figure 2) . [41] [42] [43] The high degree of phylogenetic conservation and the striking divergence of multiple C3 isoforms in certain vertebrates underscore the indispensable role of C3 in host immune surveillance. Elegant studies employing evolutionarily distant organisms have suggested that C3 preserved its immune sentinel function throughout phylogenesis, being the prime mediator of immune recognition and "non-self" discrimination in a primordial phagocytic system shared by both invertebrates and early vertebrates. 42, 43 Several lines of evidence suggest that a common ancestral complement system comprising a set of primitive C3, FB (i.e. Bf/C2 gene),
and MASP proteins was established more than 500 million years ago tion. This basic system was retained by all deuterostomes and was further diversified through gene duplications and domain rearrangements of the C3, Bf, and MASP genes. 44 These large genomic rearrangements gave rise to the first CP components (C4, C2, and C1r/ C1s), while additional domain shuffling and gene duplication events led to the emergence of the terminal lytic pathway during the branching of the gnathostomes/cyclostomes from a common ancestor of jawed vertebrates.
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F I G U R E 2 Evolution of C3 in the context of innate (complement) and adaptive immunity. The phylogenetic tree shows the early occurrence of ancestral C3 in evolution, the development of thioester-containing proteins (TEP) in insects, and the formation of increasingly mature and versatile alternative and lectin pathway (LP) systems, the striking diversity of multiple C3 isoforms in teleost fish (i.e. osteichthyes), with development of the classical pathway alongside adaptive immunity in vertebrate species C3 has been highly conserved throughout the evolution of metazoans, with its appearance predating the early divergence of the deuterostomes and protostomes from a common invertebrate ancestor.
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C3-like molecules identified in the most primitive invertebrates (cnidarian) appear to share the main structural features of their mammalian counterpart, including the thioester moiety, the anaphylatoxin domain, and the cleavage site between the α and β chains. 41 In SeC3, a C3-like gene cloned from the sea coral Swiftia exserta, most of the canonical Cys residues of human C3 are conserved, except for those linking the α and β chains. There are structural elements deduced from the cnidarian C3 sequence that suggest the presence of a three-chain structure similar to that of lamprey C3, mammalian C4, and cobra venom factor (CVF). 41 It is noteworthy that a BLAST search for predicted complement domain structures in the genomes of Cnidaria and certain protostomes (i.e. horseshoe crab) retrieved not only C3 but also Bf-related sequences, thus indicating that the core components of the complement system may have already evolved about 900-1000 million years ago. 44 The echinoderms represent a pivotal link in the evolution of C3, as the very first evidence for the presence of a functional AP was discovered in this phylum of the deuterostome lineage ( Figure 2 The branching of the cartilaginous fish from their jawless ancestors has defined a major hallmark in the evolution of the immune system. 40, 42, 43 The first core constituents of an acquired immune response began to appear in chondrichtyes (Figure 2 ), largely the emergence of MHC-like molecules and ancestral RAG1/2 genes. The concomitant emergence of the first immunoglobulins in cartilaginous fish also contributed to the development of the CP and lytic TP of complement in these species. The rest of the poikilothermic species, from teleosts to reptilians, appear to contain a well-developed complement system resembling that of homeothermic vertebrates (e.g. birds and mammals). 43 In this regard, C3 homologs with highly conserved structural features of the human C3 sequence (i.e. thioester, C3 convertase cleavage, α/β-chain processing, FI cleavage, and N-glycosylation sites) have been described in both amphibian and avian species, 50, 51 further underscoring the phylogenetic conservation of key structural elements in C3 that underlie its activation and breakdown cycle.
A prominent landmark in the phylogenetic history of C3 is defined by the divergence of the teleost fish (i.e. osteichtyes) (Figure 2 ). These bony fish species have been shown to possess a remarkably diversified complement system, with multiple isoforms of C3, C5, and FB in their plasma and distinct immune recognition specificities associated with each of these isoforms. 43, 52, 53 This diversity in complement also extends to other components, such as C5, C7, and properdin. Initially, the multiple C3 clones that were isolated from teleost cDNA libraries (four in trout, eight in carp) were simply attributed to the tetraploid state of their genome. However, the subsequent identification of multiple C3 isoforms in diploid teleost fish indicated that this striking feature of C3 gene copy variance is not restricted to tetraploid organisms. 54 A fascinating aspect of complement phylogeny revealed in this vertebrate class is that different C3 isoforms are products of distinct genes, rather than splicing variants of a common gene, suggesting that early gene duplication and copy number variation might have led to this remarkable C3 diversity in bony fish. Although most of these C3 isoforms possess the main set of structural features found in mammalian C3, they are strikingly more diverse in terms of structure and function than are their mammalian counterparts. For example, dis- convertase. 56 They also possess a functional C3aR signaling circuit, as demonstrated by the expression of C3aR on trout phagocytic cells and their ability to migrate in response to C3a stimulation.
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Comparative phylogenesis has helped to elucidate the structural determinants of C3 (also see below), including its distinct domain architecture, interacting partners, and functional implications. Complement components C3, C4, and C5 belong to the thioester-containing protein (TEP) superfamily that also includes α2-macroglobulin (α2M), the pregnancy zone protein (PZP), CD109 and CPAMD8. 42, 57 All of these proteins share homologous structural features, including a thioester domain (TED) with a unique intrachain thioester bond, eight macroglobulin (MG) domains, and a spliced CUB domain holding TED. Indeed, the spatiotemporal opsonic reactivity provided by the fascinating transformation of C3 to C3b holds the key to C3's ability to act as an efficient immune surveillance mediator. As an acute phase reactant, C3 needs to be available instantly, act rapidly, and react to various threats but not harm normal bystander cells. Instant availability is achieved by its high plasma concentration of approximately 1.2 mg/ mL, making C3 one of the most abundant plasma proteins in circulation. While it is primarily synthesized by hepatocytes in the liver and distributed intravascularly, it is important to note that C3 is produced and secreted by various cells, thereby providing a source of tissuelocalized C3. 69 The importance of local C3 production is increasingly recognized 4, [69] [70] [71] ; for example, crossover studies using C3-deficient donor or recipient mice in a kidney transplantation model have revealed that C3 produced by the donor organ rather than the systemic pool from the recipient is mainly responsible for postischemic renal failure. 72 Further exploration of the C3 distribution will prove important for a better understanding of its defense contributions in peripheral or restricted regions such as the skin, mucosa, central nervous system, and eye. At the same time, new roles have been attributed to intracellular C3, especially in lymphocytes
| REVEALING THE MOLECULAR SECRETS OF C3: INSIGHT INTO STRUCTURE-FUNCTION ASPECTS
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; the existence of a leukocyte complement system has long been postulated, 73 yet we are only now beginning to understand the implications of intracellular complement for T-cell homeostasis/differentiation and other physiological processes. 71, 74, 75 Certainly, the perception of C3 as an entirely extracellular and intravascular mediator has to be revised, and context/ location-specific activities need to be considered.
In the circulation, its high plasma levels and low biological reactivity in the native state allow C3 to act as a sentinel that can be immediately engaged after an encounter with potential insults. In fact, the only confirmed physiological ligands for native C3 are the C3 convertases and extrinsic proteases with C3 cleavage activity; a potential interaction with heme that renders C3 more susceptible to activation has been reported but requires further characterization. 76 It is fascinating that the conversion of C3 to C3b and its degradation products converts one "inert" protein into one of the most multifunctional molecules in our body. 62 Indeed, the complement map database (www.complement.
us/cmap) developed by our group, 77 shown (red box in insert); other elements have been removed added another dimension to our knowledge of the molecular mechanisms underlying complement activity. The picture emerging from these studies has been one of clever domain rearrangements and profound conformational changes that allow a tailored and coordinated transition from activation and amplification to regulation and effector signaling.
In the following sections, we summarize current structural insights into the unique design of C3 and the key processes of complement function.
| The anatomy of C3: One scaffold that determines many functions
The structure of C3 at 3.3-Å resolution was reported in 2005 and revealed an intricately shaped protein composed of 13 domains ( Figure 4A-C) . 58 The α-and β-chain each contain six individual domains ( Figure 4D) ; surprisingly, and quite unusually, a thirteenth domain is shared between the two chains. The majority of the β-chain was found to consist of a "key ring"-shaped core formed by five domains with a hitherto-undescribed fold, which were termed MG do- ).
The unusual presence of two split domains (MG6, CUB) in C3 indicates that functionally critical elements (i.e. the proC3 processing site, C3a, and CUB-TED) were added by gene insertion during evolution and assumed increasing importance in host defense. 58 The arrangement of the 13 domains in native C3 largely explains its relatively inert nature when compared to its cleavage fragments. 
| Activation in variations: From tick-over to opsonization
Despite sharing the same domain organization with native C3, the hy- ). The location of the exposed thioester bond in C3b is highlighted in yellow by studies with monoclonal antibodies that revealed comparable neoepitopes after conversion of C3 to either C3(H 2 O) or C3b. 78, 83 Hydrogen-deuterium exchange mass spectrometry (HDX-MS) identified several areas with changes in solvent accessibility upon hydrolysis of C3, particularly in the α-chain and its TED domain. 84 Detailed mechanistic insights were offered by electron microscopy (EM) studies suggesting that native C3 represents a "kinetically trapped" conformational state, in which the bulky ANA domain acts as a "door stop" to prevent the formation of the reactive conformer. 85 In an unfavorable high-energy (and therefore rare) event, potentially enabled by unfolding of MG6, ANA may slip through the key ring of the MG core, leading to an irreversible conformational change with an extended TED-CUB and exposed thioester. In contrast to its functional cousin, C3b is the best-characterized C3 fragment, with several high-resolution crystal structures describing this key opsonin in isolation or in complex with various ligands. 29, [90] [91] [92] [93] [94] [95] With the notable exception of one study, which has meanwhile been 
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Of equal importance is that the fact that the transformation of C3 to C3b reveals several previously cryptic binding sites that define its versatile involvement in activation, regulation, and signaling. For example, the repositioned CUB is involved in binding both the convertase precursor FB and most regulators of the RCA family, including CR1/CD35, CD46, CD55, and FH. 29, 90, 92 In the case of CRIg, the binding site for this receptor is located in the key ring area (MG3-6, LNK) that is present in both C3 and C3b; here, the specificity for C3b is determined by rearrangements of the MG3 and LNK domains upon activation. ) to increase the stability of the complex.
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The resulting crystal structure at 2.2-Å resolution revealed that CVF and presumably, by analogy, C3b mainly interact with FB at its head and shoulder region via domains MG2, MG6, MG7, CUB, and CTC.
Most of the contacts are provided by the Ba segment of FB, whereas the interface with the Bb segment is restricted to the CTC domain of CVF. In agreement with the long-standing notion that convertase formation is magnesium-dependent, the distorted metal-ion-dependent adhesion site (MIDAS) of FB was thought to adopt a high-affinity state in the CVF-bound form that chelated a Mg 2+ ion together with the C-terminus of CVF. In contrast, and quite surprisingly, the rest of the FB structure, and in particular the catalytic region, shows little to no change when compared to free FB, thereby leaving critical questions concerning convertase formation unresolved.
An important breakthrough in this endeavor came with the use of the bacterial complement inhibitor SCIN (see below), which had previously been shown to trap the AP C3 convertase in a kinetically stable yet inactive state. 103, 104 Indeed, in vitro convertase formation in the presence of SCIN resulted in stable complexes that could be crystallized at 3.9-Å resolution. 93 The crystal structure showed a dimeric and symmetric complex formed by two C3b, Bb, and SCIN molecules each (i.e. C3b 2 Bb 2 SCIN 2 ). When extracted from this structure, the two C3bBb complexes were highly comparable and showed that, like the CVF-FB structure, Bb was mainly bound to the CTC domain of C3b,
suggesting that the high-affinity MIDAS state is maintained. As a result of this interaction, Bb appears to "dangle" from the top of C3b in the final AP C3 convertase. The dimeric nature of the SCIN-stabilized convertase complex also revealed critical information about potential substrate binding and processing. Intriguingly, the data showed that the two copies of C3b were dimerizing at a region that is retained in both C3 and C3b, pointing to a potential contact site between the C3 substrate and convertase-forming C3b. Indeed, replacement of one , and FI (2XRC) were used in PyMOL. For visualization purposes, the closed form of C3bB was generated by using FB from CVF-FB (3HS0), Ba was extracted from the FB structure, full-length FH was composed of five copies of FH [1] [2] [3] [4] , and a hypothetical iC3b model was prepared using the structures of C3d and C3c (2A74). The model of C3 bound to C3bBb was prepared as described in, 93 Taken together, these structural and additional binding studies provide fascinating insights into an intricate molecular mechanism tailored for instant, yet controlled, tagging of targeted particles ( Figure 5 ). , no significant binding of Bb to C3b can be observed ( Figure 5B ). 93 Thereby, convertase activity relies on a constant supply of FB and the generation of new C3bBb complexes to maintain or even amplify the opsonic response. Moreover, this mechanism provides a basis for the ability of complement regulators to extrinsically control complement activation on host surfaces and confer selectivity between self and non-self ( Figure 5B ).
| A tale of two activities: A common binding mode defines regulatory functions
The N-terminal four domains of the soluble AP regulator FH exert both decay acceleration and CA. Crystallization of the C3b-FH [1] [2] [3] [4] complex at 2.7-Å resolution therefore provided an important starting point for studying the molecular basis of these two major regulatory mechanisms. 92 The structure revealed that FH at the cost of dual activity. 29 In addition to improving our understanding of the molecular mechanisms of complement regulation, these C3b-RCA structures have already become and will continue to be essential for deciphering the functional consequences of the diseaserelated mutations and polymorphisms of RCA proteins. ; of note, CRIg may also exert AP-specific regulatory functions by interfering with the binding of C3 to C3bBb and was recently reported to act as a direct PRM for Gram-positive bacteria.
112,113
The CA of certain RCAs initiates the degradation of C3b to iC3b by FI through the release of the C3f peptide from the CUB domain. There The FI-mediated cleavage in CUB to form iC3b presumably leads to a degradation of the domain, thereby removing the RCA-binding site but providing access to sites for complement receptors CR2 and CR3 that were sterically restricted in C3b. These sites are also present in C3dg, although the release of the C3c segment eliminates the MG key ring that harbors a binding site for CRIg in C3b and iC3b. The structures of C3 (PDB 2A73), C3b (2I07) and C3d (1C3D) were used for this figure; the hypothetical structure of iC3b was generated using the structures of C3c (2A74) and C3d connected by a freeform line. The color scheme defined in Figure 4 was used to color individual domains MG4 interface. 115, 117 As this area is preserved between C3b and iC3b, intracellular transformations would not account for the iC3b selectivity of CR4; the authors therefore speculated that the more flexible orientation of iC3b on the surface determines opsonin selectivity. 117 Additional studies may be needed to fully explore the distinct binding modes of CR3 and CR4 toward complement opsonins.
The final transformation of iC3b to C3dg can only be mediated by CR1/CD35, but the molecular determinants of this enhanced CA are still being investigated. Although it has been shown that C3dg
(40 kDa) can be further processed to C3d (35 kDa) after cleavage of the C3g peptide by various proteases in vitro, this transformation is currently not considered to be physiologically relevant under most circumstances. 118 With the removal of the C3c segment, including its MG core, C3dg loses the ability to bind to CRIg. The interaction with CR2, however, and the associated B-cell stimulation function, are fully preserved in C3dg. In fact, the comparatively small size, high stability, and maintained B-cell activity make multimeric C3d a candidate for the development of novel vaccine adjuvants. 119, 120 Although CR3 has long been considered to have strict opsonin specificity for iC3b, the above-mentioned molecular studies have confirmed the existence of a high-affinity binding site in the TED domain. 115 Direct binding studies confirmed that the recombinant α M I domain of CR3 interacts with iC3b, C3dg, and C3d but not with C3b. 116 In vitro, we were further able to show that densely C3dg-opsonized erythrocytes from patients suffering from paroxysmal nocturnal hemoglobinuria (PNH) are recognized and phagocytosed in a CR3-dependent manner, suggesting a physiological role for the C3dg-CR3 interaction. 116 Whether this route is dependent on C3dg density and how it compares kinetically with other uptake mechanisms in vivo remain to be further investigated.
| A FORCE THAT NEEDS TO BE CONTROLLED: C3 AS A MICROBIAL IMMUNE EVASION TARGET
The central role of C3 and the AP C3 convertase in the clearance of microbial intruders renders the C3 axis a major target in the immune evasion strategies employed by many human pathogens. 129 In all these and many other cases, pathogens exploit the physiological host's complement regulators to control convertase activity and degrade C3b. Of note, this successful strategy of non-self protection may be translated into therapeutic approaches ( Figure 7A ); for example, our group has developed a FH-binding peptide that can be coated on biomaterial and cell surfaces, recruits FH and thereby protects the coated material from complement attack via the AP.
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Orthopox viruses have found a distinct approach for harvesting the regulatory power of RCA: rather than recruiting host regulators, they express RCA mimics. Despite being much smaller than FH, some of these mimics combine strong DAA and/or CA activities with surface-binding capacity in just four domains. 132 Examples include the smallpox inhibitor of complement enzymes (SPICE) and the vaccinia virus complement control protein (VCP); even though these proteins only differ in 11 aa, their complement-inhibitory activity can vary by several orders of magnitude. 133 In a recent structural analysis, we have shown that SPICE indeed exhibits the same general binding mode for C3b as does human RCA, most closely resembling the binding of CD46
and FH. 29 Viral RCA mimics are not unique to poxviruses, though, and are also expressed by certain herpes viruses (e.g. KAPOSICA from the Kaposi's sarcoma-associated herpesvirus). 132 In addition, some herpes viruses also utilize non-RCA-based complement inhibitors. 62, 132 For example, glycoprotein C from herpes simplex type 1 (gC-1) has been
shown to bind to C3c-containing forms of C3 and impair the binding of properdin and C5, thereby blocking AP-mediated hemolysis. 134 Of note, gC-1 is among the very few ligands with activity toward native C3, even though its main inhibitory activity appears to be exerted at the level of C3b.
Potentially, the most versatile arsenal of complementmodulating strategies, many of which target C3 activation, has thus far been reported for the major human pathogen Staphylococcus aureus. 121, 123 Although mechanisms that engage or enhance RCA binding have also been described for S. aureus, [135] [136] [137] two unique protein families act through direct interactions with C3b. Members of both the extracellular fibrinogen-binding protein (Efb) and staphylococcal complement inhibitor (SCIN) family have been shown to impair complement activation by interfering with the AP C3 convertase ( Figure 7B ). Intriguingly, especially considering the structural similarity between the two families, they employ highly distinct mechanisms to achieve this goal. 28, 138 The C-terminal domain of Efb (i.e. Efb-C) strongly binds to TED-containing forms of C3, including native C3, C3(H 2 O), C3b, iC3b, and C3dg. 139, 140 Despite being the most likely target for a C3-directed complement inhibitor, C3b was found to be the weakest binder in an initial interaction profiling.
This result was attributed to the fact that, according to available crystal structures, the Efb binding site is not readily accessible in C3b. 140 It was subsequently revealed that C3b-bound Efb-C acts like a wedge to stabilize a conformation of C3b in which the TED is dislocated from the position that it assumes in all the available crystal structures. 135 Propagation of this distortion along the CUB domain into the shoulder region of C3b allosterically impairs the binding of FB to C3b, thereby largely reducing the formation of the AP C3 convertase ( Figure 7B) . 135 In addition, Efb-C has been reported to interfere with B-cell activation, based on its ability to block the interaction between C3dg and CR2/CD21, which is part of the B-cell co-receptor complex. 141 SCIN proteins, on the other hand, have been shown to directly and unrestrictedly interact with the shoulder region of C3b. 93, 103 Binding to this functional hotspot on C3b distinctively affects the interaction with FB and FH.
Although SCIN partially impairs the binding of intact FB to C3b, the main inhibitory effect is achieved via its ability to potently intercalate with C3bBb in the assembled convertase. As a consequence, SCIN stabilizes the AP C3 convertase and traps it in an inactive state that prevents further cleavage of C3 ( Figure 7B ). 93, 103 As mentioned above, this stabilizing effect was successfully utilized to enable the crystallization of the otherwise unstable C3 convertase. 93 The resulting SCIN-stabilized convertase is essentially resistant to decay acceleration by FH. 103 Furthermore, SCIN-induced dimerization masks functional sites in C3b, including those involved in signaling via CR1 and CRIg.
142
Although most organisms employ C3 for defensive purposes, or try to evade its antimicrobial activity, at least one family of predatory animals has learned to shape the potent effector function of C3 into a tool for stunning its prey. CVF, found in the snake venom of certain cobra species, shares profound sequence homology with C3b/C3c; although the three-chain protein is devoid of a TED, it still contains a CUB domain. 143 In plasma, CVF is able to assemble AP C3 convertases with human FB and FD that are kinetically much more stable than C3bBb (half-life of 7 hours compared to approximately 3 minutes) and virtually resistant to RCA-mediated regulation. As a consequence, CVF leads to a depletion of C3 stores with rapid release of anaphylatoxins, which together increase the vascular permeability and facilitate distribution of the venom in the prey. As mentioned above, CVF has been used to study the formation of the pro-convertase; in addition, it has been utilized in animal models to transiently deplete C3, and a humanized form has been considered for therapeutic purposes. 
152
Awareness of the health status of C3-deficient individuals after reaching adulthood would be of great value to us in understanding the relative contribution of C3 to immunity during aging.
In line with the concept that C3dg acts as adjuvant in the activation of B cells and antibody production, 119 differential ability in mounting antibody responses toward specific antigens after vaccination of C3-deficient patients has previously been reported. 153 Furthermore, extremely low levels of total IgG4 have been determined in some of the patients. [153] [154] [155] [156] In addition, recent reports have described impaired T-and B-cell responses ex vivo when lymphocytes from C3-deficient patients are used. 149, 154, 157 Because information about these patients is scant after the initial report describing the deficiency, it is unclear how these observations relate to in vivo situations. renal fibrosis. 179 In such diseases, the outcome is determined by how the mutation affects the regulation of C3b or the stability of the AP C3 convertase. The majority of C3 mutations affect the interactions with the regulators FH, MCP, CR1, and also FB. In these patients, the dissociation of the C3 convertase is inefficient, and C3b has a reduced rate of conversion to iC3b, leading to increased complement deposition and tissue damage. 167, [180] [181] [182] In addition to the diseases described above, C3 is an acute phase protein and can be involved in virtually any inflammatory condition.
Increased levels of C3 and/or C3 activation fragments in the circulation are observed in numerous conditions, including neurological and cardiovascular diseases, obesity, asthma, cancer, periodontitis, and transplant rejection. 4, 145, [183] [184] [185] [186] [187] [188] [189] Excessive complement activation contributes to the disease pathogenesis by fueling the inflammatory process and inducing tissue damage, highlighting the profound importance of the tight regulation of complement activation in the maintenance of homeostasis.
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| THERAPEUTIC CONTROL OF C3 ACTIVATION
Given the growing recognition of complement's involvement in various disease processes and the technological advances made in recent decades, the complement system has moved into the spotlight of pharmaceutical and biotechnological companies. Because of its early and widespread involvement in danger sensing and inflammatory processes, complement is now considered an attractive therapeutic target for a broad spectrum of immune, thrombo-inflammatory, and age-related diseases, as well as in transplantation medicine and beyond. 4, 108, 162 With two compounds in the clinic, several candidates in clinical trials, and numerous promising concepts in preclinical development, complement-targeted drug discovery has become a thriving field, and we refer to specialized reviews for an overview of past and recent advances. 161, 145, 162, [190] [191] The central role of C3 in complement activation, amplification, and effector generation naturally renders this protein an interesting target for therapeutic intervention. So far, however, the complementinhibiting drugs available in the clinic, i.e. the anti-C5 antibody eculizumab (Soliris, Alexion) and various preparation of C1-INH (e.g.
Cinryze, Shire) target peripheral steps such as initiation or effector generation. Fortunately, several candidate drugs acting at the level of C3 activation are currently in development; they either act on C3 itself or on the C3 convertase ( Figure 8 ). 190, [192] [193] [194] With its high plasma concentration (approximately 5 μM) and metabolic turnover, native C3 has traditionally been considered a challenging target for therapeutic intervention. Moreover, and in contrast to "druggable" targets in the classical sense such as serine proteases, kinases, or GPCRs, the functional activity of C3 primarily relies on conformational changes and protein-protein interactions that are not easy to impair. However, largely thanks to the unprecedented biochemical and structural insights into C3 and its various functions discussed above and the tireless work of several academic and industrial groups in advancing the initial concepts, we are closer to having the first C3-targeted drugs reach clinical accessibility than ever before. 190, 192, 194 In addition to offering an urgently needed new avenue for treating complement-related diseases that do not adequately respond to existing options, the availability of potent molecules that inhibit distinct steps of C3 activation should further advance our knowledge of the role of C3 in health and disease.
| Taming the convertase
As the powerhouse of complement activation and amplification, the C3 convertases are an obvious promising choice to alleviate the detrimental effects of complement activation; this assertion is underscored by the fact that the majority of complement regulators, as well as many evasion proteins produced by human pathogens, interfere with the assembly, activity, or stability of the convertases (see above). Antibodies and molecules that specifically inhibit either C1s or members of the MASP family are therefore being developed. 161, 190 The indications for such compounds are mainly focused on diseases with an established strong involvement of a distinct initiation pathway, as is the case for the CP in autoimmune hemolytic anemia for instance.
For indications with a more complex initiation profile or predominant exacerbation via the amplification loop, targeting the AP C3 convertase might prove more rewarding.
As in the case of the above-mentioned approach for the CP/LP, inhibiting the serine proteases that drive the formation of the active convertase is a suitable approach. 190, 192, 194 Currently, the main focus appears to be on FD, which is the partner with the lowest abundance and which represents a bottleneck in convertase formation. For example, Genentech has developed an antibody fragment including PNH and ischemia-reperfusion injury 197, 198 ; Alexion has evaluated TT30 in a phase I trial but has not announced further development plans.
Another approach to reducing the size of FH while conferring enhanced targeting properties has been taken by our group and others. [199] [200] [201] Analysis of the crystal structures of C3b-FH [1] [2] [3] [4] and C3d-FH [19] [20] have shown that the two functionally important termini are situated in close proximity and can be bridged to produce a mini-FH protein with 6 instead of 20 domains. 199 Interestingly, the recombinant construct not only maintains binding affinity for C3b
and GAG but also shows higher activity in AP inhibition models than does FH. This mini-FH achieves stronger binding to the late-stage opsonins iC3b/C3dg, likely because of the better accessibility of the C3d binding site in FH [19] [20] after the removal of the middle segment and because the connectivity between the domain areas plays an important role. 202 As a consequence, mini-FH analogs are ideally targeted toward host surfaces under complement distress. Despite missing the surface-recognition part of FH, the splice variant FHL-1 may also be considered as a therapeutic option (e.g. for local applications) because of its small size and presumably improved tissue penetrance. 203 More recently, CRIg and the LP regulator MAP-1 have been explored as means of directing regulators to sites of ongoing complement activity. 204, 205 The modular organization of most complement regulators has certainly opened fascinating possibilities for inhibitor design.
F I G U R E 8 Therapeutic intervention strategies at the level of C3. Inhibition of complement activation at the level of C3 is primarily achieved through three major routes. Although FB and FD inhibitors (small molecules or antibodies) prevent the formation of the AP C3 convertase, engineered versions of complement regulators such as mini-FH or TT30 block convertases by accelerating their decay and enabling the proteolytic degradation of C3b by factor I; both approaches are specific for the AP. C3 inhibitors of the compstatin family (e.g. Cp40) bind to C3 and protect the substrate from being activated by any of the C3 convertases. Complement-targeted drugs available in the clinic, i.e. the anti-C5 mAb eculizumab and C1-inhibitor preparations, which all act at peripheral steps of the cascade, are also shown in the scheme
| Protecting the substrate: Direct inhibition of C3 by compstatin analogs
Convertase inhibitors can exhibit powerful activity but are typically pathway-specific and prevent C3 activation via either the CP, LP, or AP. In some situations, however, total blockade of C3-mediated opsonization and effector generation is desired. Such an effect can be achieved by peptides of the compstatin family, which bind to a functional hotspot on the C3 substrate and prevent its activation by any of the C3 convertases. 206, 207 Originally discovered by our group in 1996 during phage-display peptide library screening, 208 the compstatin family has since grown to include several distinct analogs with unique properties, two of which are currently in clinical development. 190, 206 The phage display-derived compstatin was identified as a cyclic peptide of 13 amino acids that binds to human C3 (and C3c-containing fragments) and potently inhibits both AP and CP/LP-induced C3b deposition. 208 Importantly, compstatin showed a narrow species specificity toward C3 from humans and non-human primates. 209 From a molecular perspective, the cyclic nature of the peptide was found to be essential, and several key residues were identified. 207 Based on this information, and in the absence of structural data, the first rounds of optimization using natural amino acids resulted in an analog (4W9A)
that was acetylated at the N-terminus and included two amino acid substitutions (V4W and H9A), thereby gaining a 13-fold increase in affinity. 207, 210 The use of non-natural amino acids, and in particular use of an indol N-methylated variant of Trp in position 4, improved the activity gain to more than 260-fold over the original compstatin. 207, 211, 212 Early on, some of these compstatin analogs showed promising efficacy data, for example in ex vivo models of kidney transplantation or biomaterial-induced complement activation. [213] [214] [215] The lead analog at that point (2006) was licensed to Potentia Pharmaceuticals; this analog performed successfully in phase I trials in AMD but did not reach the desired endpoints after administration of much lower doses in subsequent phase II trials. Meanwhile, the technology was transferred to Apellis Pharmaceuticals; although the unmodified compound (APL-1)
is being considered for use in COPD, a PEGylated derivative (APL-2) has been clinically developed for local administration in AMD and for systemic application in PNH. 161, 190 The lack of a crystal structure made it challenging to obtain a rational optimization of this promising lead compound. In addition, its molecular mechanism of action has long been unclear, as biochemical analyses have localized the compstatin binding area to a part of the β-chain that was considered distant from both the C3a cleavage site and the FB binding region. 216 These gaps were filled in 2007 with the publication of a crystal structure of C3c in complex with the compstatin analog 4W9A. 217 The structure revealed that compstatin binds to a shallow groove at the interface between MG4 and MG5 on the outside of the key ring of C3. An early hypothesis that this binding might interfere with the interaction of the C3 substrate and the convertase was subsequently confirmed by the structure of the SCIN-stabilized C3bBb complex (see above). 93, 217 Superposition of these structures indeed showed that the compstatin binding site is located on the C3/C3b dimerization interface, which is presumed to be essential to allowing the binding and activation of C3. Although the binding of a second compstatin molecule to C3b of the convertase complex can enhance this effect in the case of the AP, the potent inhibition of CP/ LP-mediated complement activation suggests that blockage of the substrate is sufficient to achieve the inhibitory effect.
Binding site analysis and the use of tools from peptide and medicinal chemistry, including backbone N-methylation, have enabled the generation of next-generation analogs with a marked improvement in C3 binding affinity and inhibitory activity. 163, 206, 211, 218 The lead analog, Cp40, was the first analog with subnanomolar binding affinity for C3 (K D =0.5 nM), marking an approximately 5000-fold improvement over the initial compstatin. 163 Structural analysis showed that N-methylation of Gly induces a bound-like conformation of Cp40 in solution, which may improve target binding. Moreover, the addition of a D-Tyr at the N-terminus extends the binding site and forms additional contacts with C3. 163 Despite the strong activity gain, Cp40 maintains its species specificity for human/primate C3. The tight target binding and the high plasma concentration of C3 also contribute to the unique pharmacokinetic properties of Cp40, which remains in the circulation much longer than do typical peptide drugs. 163, 206 
| Moving ahead toward C3 inhibitors in the clinic
Although the development of C3-level complement inhibitors with clinical potential took substantially longer than expected, several highly promising candidates are now waiting in the wings.
The overcoming of technical hurdles played an important role in this advancement. As demonstrated by Cp40, feasible treatment schemes for maintaining target-saturating levels may even be achieved for abundant targets such as C3. Although pharmacokinetic parameters may be even further improved by chemical modifications, for example by employing PEGylation or albumin-binding moieties, 219 ,231 the cost-benefit ratio needs to be carefully considered in each case. Another game-changer in the development of therapeutic C3-targeted drugs is the regained trust in complement inhibition in general, including the blockage of C3. 4, 190, 192 The clinical experience has been largely positive and, in the case of eculizumab, the potential risk of infection by meningococci can be addressed by vaccination. For C3-targeted inhibitors, such antiinfective strategies may need to be expanded to other encapsulated bacteria such as pneumococci. Importantly, the risk of C3 inhibition needs to be considered in the right context, as local, systemic, acute,
and chronic treatment present highly distinct situations. The clinical trials that are being conducted at this point and in the near future will be critical for advancing our current mainly hypothetical questions about the benefits and risks of blocking C3 activation in humans to evidence-based discussions. 
| CONCLUSION
